MeiraGTx (MGTX) – Investment Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of MeiraGTx (NASDAQ: MGTX) recently:

• 11/24/2025 – MeiraGTx is now covered by analysts at HC Wainwright. They set a “buy” rating and a $20.00 price target on the stock.
• 11/24/2025 – MeiraGTx is now covered by analysts at HC Wainwright. They set a “buy” rating and a $20.00 price target on the stock.
• 11/15/2025 – MeiraGTx was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/14/2025 – MeiraGTx had its price target raised by analysts at Royal Bank Of Canada from $12.00 to $16.00. They now have an “outperform” rating on the stock.
• 11/11/2025 – MeiraGTx had its price target raised by analysts at Piper Sandler from $28.00 to $30.00. They now have an “overweight” rating on the stock.
• 11/11/2025 – MeiraGTx had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $35.00 price target on the stock.
• 10/21/2025 – MeiraGTx is now covered by analysts at Raymond James Financial, Inc.. They set a “strong-buy” rating and a $29.00 price target on the stock.
• 10/8/2025 – MeiraGTx had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling at MeiraGTx

In other MeiraGTx news, CEO Alexandria Forbes sold 47,500 shares of the company’s stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $8.39, for a total value of $398,525.00. Following the sale, the chief executive officer owned 1,313,983 shares in the company, valued at approximately $11,024,317.37. The trade was a 3.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Richard Giroux sold 24,000 shares of the company’s stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $8.87, for a total transaction of $212,880.00. Following the completion of the sale, the chief financial officer directly owned 829,494 shares in the company, valued at approximately $7,357,611.78. This represents a 2.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 7.50% of the company’s stock.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.